

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

Mino

RRID:CVCL_1872

Type: Cell Line

Proper Citation

RRID:CVCL_1872

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1872

Proper Citation: RRID:CVCL_1872

Description: Cell line Mino is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Mantle cell lymphoma

Defining Citation: [PMID:12127561](#), [PMID:12683869](#), [PMID:21746927](#), [PMID:22460905](#), [PMID:24362935](#), [PMID:25315077](#), [PMID:25355872](#), [PMID:25688540](#), [PMID:25960936](#), [PMID:26194763](#), [PMID:28196595](#), [PMID:29666304](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank)., Part of: LL-100 blood cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Mino

Synonyms: MINO

Cross References: EFO:EFO_0022501, AddexBio:C0003033/4947, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-3000, BioSample:SAMN03471705, BioSample:SAMN10988480, cancercellines:CVCL_1872, Cell_Model_Passport:SIDM01667, ChEMBL-Cells:ChEMBL4523520, ChEMBL-Targets:ChEMBL4523551, CLS:305513,

Cosmic:2078181, Cosmic:2088019, Cosmic:2756236, DepMap:ACH-000220, DSMZ:ACC-687, DSMZCellDive:ACC-687, GEO:GSM629496, GEO:GSM629497, GEO:GSM887321, GEO:GSM888397, GEO:GSM907522, GEO:GSM1044970, GEO:GSM1044971, GEO:GSM1044972, GEO:GSM1044973, GEO:GSM1670110, GEO:GSM2322625, IARC_TP53:17152, LiGeA:CCLE_916, Lonza:165, PharmacDB:Mino_932_2019, Progenetix:CVCL_1872, PubChem_Cell_line:CVCL_1872, Wikidata:Q54905748

ID: CVCL_1872

Record Creation Time: 20220427T220809+0000

Record Last Update: 20260815T234625+0000

Ratings and Alerts

No rating or validation information has been found for Mino.

No alerts have been found for Mino.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Roleder C, et al. (2026) Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma. Cancer research communications, 6(5), 1192.

Dell'Aversana C, et al. (2026) UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies. Journal of hematology & oncology, 19(1).

Lowe E, et al. (2025) Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activity. The Journal of pharmacology and experimental therapeutics, 392(8), 103634.

Mani R, et al. (2025) TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. iScience, 28(6), 112584.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell, 188(2), 331.

Roider T, et al. (2021) The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. International journal of cancer, 148(1), 150.

Sadras T, et al. (2021) Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. *Molecular cell*, 81(10), 2094.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. *Cell reports. Medicine*, 2(7), 100350.

Donovan KA, et al. (2020) Mapping the Degradable Kinome Provides a Resource for Expedited Degradation Development. *Cell*, 183(6), 1714.

Marchesini M, et al. (2020) Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia. *Cell chemical biology*, 27(6), 678.

Perrot I, et al. (2019) Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. *Cell reports*, 27(8), 2411.

Steinberger J, et al. (2019) Tracing MYC Expression for Small Molecule Discovery. *Cell chemical biology*, 26(5), 699.